News

Acer Therapeutics Announces In-license of Osanetant from Sanofi

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist     NEWTON, MA – January 2, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and...

read more

News

Acer Therapeutics Announces In-license of Osanetant from Sanofi

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist     NEWTON, MA – January 2, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and...

read more